Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

GlobeNewsWire • Oct 20, 2026

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA's valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of its rival's acquisition value. Miplyffa's US launch is slow but stable; key risks are insurer restrictions and potential sales declines, with Europe currently valued at zero.

Seeking Alpha • Oct 15, 2026

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond initial estimates.

Seeking Alpha • Oct 6, 2026

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Zevra Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.

GlobeNewsWire • Sep 2, 2026

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium. “These presentations further expand the growing body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC,” said Caroline Hastings, MD, Professor of Pediatrics, UCSF Benioff Children's Hospital Oakland.

GlobeNewsWire • Aug 25, 2026

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).

GlobeNewsWire • Aug 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire • Aug 13, 2026

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.

MarketBeat • Aug 6, 2026

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026